Nanotherapeutics for the Treatment of Hepatocellular Carcinoma E-Book
117,96 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Sprache: Englisch
Hepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemotherapeutic agents which is also reflected in the high mortality of the disease. Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes. Thus, nanotherapeutics have shown considerable potential and there is tremendous impetus for rapid translation from the pre-clinical to the clinical domain to significantly prolong the survival in HCC.
In Nanotherapeutics for the Treatment of Hepatocellular Carcinoma, authoritative experts of the field have explored the important aspects of nanotherapeutics against HCC. The book exhaustively, vividly and explicitly describes the molecular pathogenesis, diagnostic aspects and nanotherapy of HCC, while also highlighting the challenges of conventional therapy and the benefits of nanotherapeutics. Chapters of the book also cover recent investigations of nanotherapeutics against HCC, types of nanomedicines, recent patents, commercially available nanotherapeutics and a future perspective to give a comprehensive review of the topic to readers. In addition to these defining features, the book provides several references for further reading. The book is an ideal resource on HCC nanotherapeutics for medical and pharmacology postgraduate students, faculties, researchers, and biomedical scientists working on HCC and nanotherapy.
Das E-Book können Sie in Legimi-Apps oder einer beliebigen App lesen, die das folgende Format unterstützen:
Seitenzahl: 1100
Veröffentlichungsjahr: 2022
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
Preface
Biswajit MukherjeeCancer is a fatal disease, and hepatocellular carcinoma (HCC) has become a predominant cause of cancer-related deaths. Existing therapy against the HCC is inadequate for several reasons, such as late diagnosis, HCC being asymptomatic at the initial stage, liver resection or transplantation as an advisable treatment option, non-availability of the liver for transplantation, rejection of the transplanted liver by the body, nonspecific chemotherapy that causes damages to cancerous as well as normal hepatic cells, fast rejection of free drug/small molecules from hepatic tumors, the formation of resistance against chemotherapy by cancer cells, and the dearth of the non-targeted drug system.
Hence, it is essential to deliver the drug/formulation specifically to the cancer cells to induce apoptosis and reduction or cessation of proliferation, keeping normal healthy cells unaffected. Nanoscale drug delivery systems show such capabilities for targeted drug delivery to the HCC specific cells, avoiding the normal cells. Several investigations showed how productive and beneficial nanotherapy is in successfully delivering a drug in HCC cells by specifically targeting cancer cells. Commercial availability of the new formulations has been explored and is already in the pipeline of commercialization. Hence, it is important to understand nanotherapy and its correlation to HCC patients to control HCC in a better and satisfactory way. However, technology still needs to be improved for ease of manufacturing and cost-effective production of nanotherapy against HCC. More efforts are required to concentrate on the targeting aspects of the formulation of HCC cells.
The content of this book would be suitable for medical students, medical faculties, researchers of medicines, biomedical scientists, and researchers studying and working in hepatocellular carcinoma and nanotherapy. In this book, several chapters by the authoritative experts of the field have explored all the areas of nanotherapeutics against HCC. The readers will benefit from the knowledge shared by the experts. Thus, nanotherapeutics have shown considerable potential and tremendous impetus for rapid translation from the pre-clinical to the clinical domain to significantly prolong the survival in HCC. Based on the recent investigations, the book is intended to highlight the impact of nanotherapeutics in HCC treatment and its future direction.
List of Contributors
Hepatocellular Carcinoma: Diagnosis, Molecular Pathogenesis, Biomarkers, and Conventional Therapy
Biswajit Mukherjee*,1,Manasadeepa Rajagopalan2,Samrat Chakraborty1,Prasanta Ghosh1,Manisheeta Ray1,Ramkrishna Sen1,Iman Ehsan1Abstract
Hepatocellular carcinoma (HCC), the most common liver malignancy, has been a significant cause of cancer-related deaths worldwide. Cirrhosis, hepatic viral infections, fatty liver, and alcohol consumption are notable risk factors associated with HCC. Furthermore, a crucial challenge in the therapeutic management of HCC patients is the late-stage diagnosis, primarily due to the asymptomatic early stage. Despite the availability of various preventive techniques, diagnoses, and several treatment options, the mortality rate persists. Ongoing investigation on exploring molecular pathogenesis of HCC and identifying different prognostic and diagnostic markers may intervene in the conventional mode of treatment option for better therapeutic management of the disease. Subsequently, tumor site and its size, extrahepatic spread, and liver function are the underlying fundamental factors in treating treatment modality. The development in both surgical and non-surgical methods has resulted in admirable benefits in the survival rates. Understanding the mechanism(s) of tumor progression and the ability of the tumor cells to develop resistance against drugs is extremely important for designing future therapy concerning HCC. This chapter has accumulated the current literature and provided a vivid description of HCC based on its classification, risk factors, stage-based diagnosis systems, molecular pathogenesis, prognostic/diagnostic markers, and the existing conventional treatment approaches.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a malignant form of highly progressive primary liver cancer. It originates from hepatocytes. Around 0.9 million new cases and 0.8 million deaths of liver cancer patients globally have been reported in 2020 by the International Agency for Research on Cancer. Increasing mortality rates and late-stage diagnosis often make HCC a tremendous challenge for its better therapeutic management. Hence patients detected with early-stage HCC possess a greater chance of getting a positive response with different treatment protocols. HCC may not show any symptoms at an early stage of cancer. Still, with the disease's progress, the symptoms such as pain at the right side of the upper abdominal part, fatigue, bloating, loss of appetite, nausea, vomiting, fever, pale bowels, and dark urine may appear. Several risk factors are associated with infected livers, fatty liver, and chronic alcohol consumption in a high amount. In the case of cirrhotic liver, the treatment decisions become limited except the finding of liver transplantation. Due to cirrhosis, any planned liver resection gets limited since the remaining liver may not tolerate volume loss and regenerate. However, an effective treatment method for HCC and cirrhosis of the liver is orthotopic liver transplantation (OLT), but early-stage HCC detection is required for such cases. HCC and cirrhosis are more significant in patients with hepatitis C virus (HCV) infection.
Several upstream or downstream regulators in various signaling cascades activate/ inactivate to continue uncontrolled proliferation in the cancerous processes (Mello and Attardi 2018, Nam and van Deursen 2014, Dolgin 2017). Epigenetic alterations may cause DNA methylation and other histone modifications that confer significant alteration to the genome. The epigenetic modification may inactivate tumor suppressor genes or cause the sudden activation of oncogenes. These may ultimately cause cancer (Kanwal and Gupta, 2012). Thus, a vivid understanding of the tumor microenvironment only can lead to exploring molecular pathogenesis more accurately and minutely to access the more appropriate and convincing therapeutic management of HCC. Suitable diagnostic and prognostic biomarkers are still essential to identify the disease early as the treatment decisions strictly depend on the tumor stage.
Hence, in this chapter, we want to introduce HCC with its classification, risk factors, and various diagnostic staging based on current literature. Tumor microenvironment and molecular pathogenesis during HCC development and progression, along with prognostic/diagnostic HCC markers, have been explored here. The existing conventional treatment approaches give a better understanding of the current way of therapeutic management of HCC.
CANCER AND ITS TYPES
The liver is the largest organ that primarily undergoes detoxification, metabolism, break-down of blood cells, protein synthesis, and bile synthesis. The liver predominantly contains hepatocytes. However, other cell types such as perisinusoidal fat-storing cells or ito cells, hepatic stellate cells, Kupffer cells, and hepatic sinusoidal endothelial cells are also available in the liver (Guyton and Hall 2006, Fox 2011). Neoplasm that grows in epithelial cells is carcinoma, whereas mesenchymal (connective tissue) origin is a sarcoma. Both types appear in the liver.
Primary liver cancer begins in the liver and secondary liver cancer cells where neoplastic cells develop in a different organ and migrate to the liver.
Primary Liver Cancer
Hepatocellular Carcinoma (HCC)
The most common primary liver cancer that accounts for nearly 75 percent of all liver cancers in adults is HCC. It originates from hepatocytes. HCC usually metastasizes to the lungs, bone marrow, and other digestive organs, including the stomach, pancreas, and small and large intestines, including the colon.
Intrahepatic Cholangiocarcinoma (Bile Duct Cancer)
Intrahepatic cholangiocarcinomas originate from epithelial cells of the cell-lining present in small bile ducts. The type accounts for 10-20% of hepatic cancers (Gupta and Dixon 2017).
Angiosarcoma and Hemangiosarcoma
They are primarily rare forms of primary hepatic cancer. Their origin is the endothelial cells of hepatic blood vessels. The reports suggest that these forms of cancer are familiar to people who had prolonged exposure to chemicals such as thorium dioxide and vinyl chloride (Molina and Hernandez 2003, Bolt 2005).
Hepatoblastoma
Unifocal immature fetal precursor liver cells seem to be the origin of this scarce hepatoblastoma. Although rare, hepatoblastoma is only seen in infants and children, usually up to three years of age. Hepatoblastoma can metastasize. (Hoshida et al., 2012, Meyers et al., 2012, Wang et al., 2013).
Secondary Liver Cancer
Secondary cancer is advanced liver cancer. The aptest cancer to spread is bowel cancer, as blood supply from the small bowel is well-connected to the liver by the hepato-portal vein. Melanoma, breast cancer, stomach, esophagus, pancreas, kidney, ovary, and lung usually spread to the liver. Secondary liver cancer is more prevalent in Australia (Cancer Council 2020).
Occasionally, secondary liver cancer appears before the diagnosis of primary cancer, and thus, primary cancer remains undiagnosed in patients who have been diagnosed with secondary liver cancer. It is also popular as a cancer of unknown primary (Hoshida et al., 2012).
DETAIL DESCRIPTION OF HCC
Hepatocellular carcinoma (HCC) is recognized as the most prevalent form of primary liver cancer as its occurrence ranges between 80-90%, among all types of primary liver cancer (Chen et al., 2019; Galun et al., 2017; Ladju et al., 2017; Li et al., 2016; Mohamed et al., 2017; Zhang et al., 2016). The majority of HCC cases in Asia and sub-Saharan Africa are due to predominantly elevated incidences of hepatitis B (HBV) virus-induced hepatic infection. Globally, the incidences of HCC show a steep rise accompanied by a high mortality rate, making HCC one of the most devastating neoplasias (Galun et al., 2017; Li et al., 2016; Zhang et al., 2016). Chronic inflammatory hepatocellular damage from various etiologies may be a risk factor for HCC (Aravalli et al., 2013; Yang et al., 2019; Yapali and Tozun, 2018). More risk factors of HCC include chronic hepatitis for hepatitis B (HBV) and C viruses (HCV) infections, vinyl chloride, tobacco, foodstuffs contaminated with aflatoxin B1 (AFB1), excessive consumption of alcohol, non-alcoholic fatty liver disease (NAFLD), obesity, diet, excessive drinking of coffee, oral contraceptives, hemochromatosis, genetic and congenital abnormalities (Balogh et al., 2016; Marrero et al., 2018). The impact of these risk factors for the development of HCC varies depending on the geographical regions, lending diagnosis, prognosis, and treatment recommendation (Marrero et al., 2010). HCC shows an extreme preference for males as compared to females. The occurrence of HCC in males is four times and eight times higher than in females in the low-incidence and high-incidence regions, respectively (Balogh et al., 2016; Marrero et al., 2018; Yapali and Tozun, 2018). The findings of the HCC BRIDGE study conducted on 18,031 patients enrolled from 42 sites in 14 different countries have revealed that the mean age for the diagnosis of HCC was 69, 65, and 62 years in Japan, Europe, and North America, respectively (Park et al., 2015). In Africa, a population-based study did not provide convincing high-quality data. The outcomes of a tertiary-referral-center-based cohort study on 1,552 patients enrolled from 14 centers in seven African countries showed that the onset of HCC diagnosis was 45 years, as found in the literature published in 2015 (Yang et al., 2015). Like diagnosis and onset, wide variations in the overall survival of HCC-patients globally occurred. The median survival of HCC-patients was drastically low in sub-Saharan Africa (2.5 months) (Yang et al. 2015; Yang et al., 2017a), indicating severe lacuna in a surveillance program and availability of productive treatment strategies. Taiwan and Japan have experienced the highest clinical outcomes in HCC-patients for the regular, extensive surveillance program. The plan consisted of an assessment of multiple tumor biomarkers, namely, alpha-fetoprotein (AFP), the Lens culinaris agglutinin reactive glycoform (AFP-L3), des-gama-carboxyprothrombin (DCP), and also imaging in the high-risk individuals by liver ultrasonography to detect unknown or suspicious liver nodules. Thus, they were capable of detecting the adults with a risk of HCC (Kudo 2018a). The clinical outcomes in China, Korea, North America, and Europe are significantly poor compared to Japan and Taiwan. It is because more than 60% of patients develop intermediate or advanced stage HCC. Egypt provided the best clinical outcome among the different African countries as patients' overall survival was significantly higher than the other sub-Saharan and East African countries. The reason could be a lesser proportion (69%) of HCC-patients transformed into an intermediate or advanced stage as compared to a higher proportion (76%) of medium and advanced-stage HCC-patients in other African countries (95%). Further, effective treatment options are accessible to a more significant proportion (76%) of HCC-patients in Egypt as compared to a low ratio (3%) of treated patients who had access to the treatment against HCC in other African countries (Yang et al., 2015; Yang et al., 2017a; Kudo 2018a; Yang and Roberts 2010).
India has also experienced a steep rise in the primary liver cancer from the last decade. Nowadays, HCC has become one of the leading gastrointestinal (GI) cancers in India (Acharya et al., 2014; Kumar et al., 2014). The consensus guidelines for tackling HCC in the USA, Europe, and North America are inadequate to address the issues related to the management of HCC in India. The most important limitation is the socio-economic condition of India. Thus the majority of Indians cannot afford the costly treatments suggested by these guidelines.
Further, the different surveillance strategies such as awareness for the interception of HCC, screening to identify high-risk groups, inability to diagnose HCC at the early stages, and inadequate availability of palliative and curative treatments lead to a diagnosis of HCC at the intermediate and the advanced forms. In 2011, the Indian National Association for Study of the Liver (INASL) had developed a Task-Force on HCC to design consensus guidelines based on clinical features of HCC, especially the disease pattern and clinical practices in India. Importantly, nationalized representative data depicting the epidemiology of HCC is not available. Cancer is not a reportable disease in India, and registries mostly have an urban focus (Kumar et al., 2014; Acharya, 2014).
The information obtained cancer registry website (www.ncrpindia.org, accessed on 11.01.21) has depicted that the last registry published by the Indian Council of Medical Research (ICMR) in 2008 provided information on all the types of cancer for a period of two years (2006-2008) (http://www.ncrpindia.org/Reports/ PBCR_2006_2008.aspx, accessed 11.01.21; https://www.ncdirindia.org/ncrp/ca/ about.aspx, accessed on 11.01.21). Besides, World Health Organization (WHO) also provided clues regarding the epidemiology of HCC in India. Based on the information supplied by the ICMR and WHO (http://www.ncrpindia.org/Reports/ PBCR_2006_2008.aspx, accessed 11.01.21; https://www.ncdirindia.org/ncrp/ca/ about.aspx; accessed on 11.01.21; http://ci5.iarc.fr/, accessed 11.01.21), the following consensus statements have been finalized by the Task-Force as described below:
(a) In India, age-adjusted incidence rates of HCC in men and women range between 0.7 to 7.5 and 0.2 to 2.2, respectively, per 100,000 populations, per year.
(b) HCC has shown a strong preference for male and male: female ratio was 4:1.
(c) The age of HCC patients showed broad variation that ranged between 40-70 years.
(d) The transformation of cirrhosis into HCC is 1.6% per year in India.
(e) 6.8/100,000 and 5.1/100,000 are the age-standardized mortality rate in men and women, respectively, in India.
(f) Most hepatic neoplasia in India is derived from cirrhosis, chronic viral hepatitis such as HBV and HCV infections, alcohol consumption, and aflatoxin exposure.
(g) Diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), smoking, and tobacco have contributed significantly to HCC development and are also considered risk factors.
(h) Data implicating the impact of the genetic predisposition for HCC are inadequate to consider it a risk factor.
Staging System in HCC
Cancer staging is a crucial aspect to provide necessary information that helps decide the best possible therapeutic management (Aravalli et al., 2013; Yang et al., 2019; Balogh et al., 2016; Marrero et al., 2018). Further, the staging system provides various valuable information such as the proper selection of primary and adjuvant therapy, helping to assess prognosis, to assist in analyzing outcomes of the therapeutic regimen/treatment strategies, and for appropriate channeling of information to avoid any uncertainty (Pons et al., 2005; Karademir 2018; Subramaniam et al., 2013). In oncology, the tumor stage has a sole impact on the prognosis of patients having a solid tumor. Thus other co-factors such as age or histologic grade are rarely considered for staging. HCC is an exceptional neoplasm as it originates primarily from underlying cirrhotic condition and, thus tumor staging and histologic grade have an impact on suitability and applicability of treatment strategies (Pons et al., 2005; Marrero et al., 2010; Marrero et al., 2018, Yang et al., 2019). The various metabolic alterations at the origin of neoplasia and the degree of hepatic impairment due to neoplastic transformation make HCC highly heterogeneous, as reported in the literature (Aravalli et al., 2013; Yang et al., 2019). Thus, the staging system's efficiency depends on its capability to address the issues such as tumor stage, liver function, and physical status on the disease's prognosis (Pons et al., 2005; Marrero et al., 2018, Yang et al., 2019). Eight different stagings belong to HCC, but no one has universal acceptance (Pons et al., 2005, Subramaniam et al., 2013; Marrero et al., 2018). Europe frequently employed the Barcelona-clinic liver cancers (BCLC) system and the Italian liver Program (CLIP), whereas Japan integrated staging (JIS) has owned in recognition as a standard system in Japan for directing liver cancer (Pons et al., 2005; Marrero et al., 2018; Yang et al., 2019).
In TNM staging, the number and size of the original tumor are denoted by T (tumor). Nodes (N) signify the presence of cancer in regional (nearby) lymph nodes. M (metastases) indicates the spreading of HCC from the primary site to a distant body part. Lungs and bones are the most preferred sites for the metastasis of HCC (Pons et al., 2005; Subramaniam et al., 2013; Karademir, 2018). The American Joint Committee on Cancer (AJCC) has approved the staging. Each stage has a characteristic number (0-4) and a letter “X”. The intensity of severity is denoted by a number. The higher number indicates more rigor than the lower number (Llovet et al., 1998; Marsh et al., 2000; Vauthey et al., 2002). For example, the score T2 indicates a giant tumor as compared to the score T1. The letter “X” marks the unavailability of clear-cut information regarding cancer. The TNM staging has exhibited significantly superior performance as a prognostic predictor for the patients undergoing surgery than those undergoing resection or transplantation. An improved TNM staging version has appeared by incorporating tumor stage and fibrosis (Szklaruk et al., 2003; Pons et al., 2005; Karademir, 2018).
Among the myriads of staging systems, the BCLC system has been maximally explored to properly assess prognosis in HCC patients (Balogh et al., 2016; Marrero et al., 2018; Liu et al., 2016). The findings obtained from a plethora of cohort studies and randomized clinical trials (RCTs) led to the development BCLC staging system (Llovet et al., 1999; Former et al., 2018). Ideally, it is a single unified proposal to establish a liaison between evaluating prognosis and selecting the most suitable treatment strategies, including their advancement to make them highly potent (Balogh et al., 2016; Marrero et al., 2018; Giannini et al., 2016). Thus, it is more likely a classification system than a scoring system (Llovet et al., 1999; Balogh et al., 2016; Former et al., 2018; Yang et al., 2019). The plan had several variables such as tumor stage, liver functional status, overall physical status, and cancer-related symptoms. BCLC acts as a bridge between these variables and various treatment option systems (Marrero et al., 2005; Cillo et al., 2006; Chen et al., 2009). Further, the global acceptability of BCLC staging as a guide for HCC treatment is maximum (Marrero et al., 2018, Yang et al., 2019). Minor tuning requires depending on some specialized individual cases, especially in patients with impaired liver function. Based on the variables mentioned above, BCLC staging assigned HCC patients into five categories, namely, 0, A, B, C, D (Cillo et al., 2006; Chen et al., 2009).
The classification of HCC-patients under various categories, namely, stage 0 (very early stage), if they have no abnormalities in liver function (Child-Pugh A), one asymptomatic tumor < 2cm without vascular invasion or satellites. The therapy recommended for stage A is resection.
Patients with Child-Pugh score A or B, a single tumor of any size or 2-3 tumors of size < 3cm, are assigned into stage A (early stage). The radical approach comprising resection, transplantation, adjuvant resection, or percutaneous treatment is recognized as optimal therapy as reported in the literature (Cillo et al., 2006; Chen et al., 2009).
Patients with Child-Pugh score A or B, multiple tumors, and without extrahepatic metastases belong to stage B (intermediate stage). Chemoembolization may be beneficial for these patients.
The stage C (advanced stage) patients have Child-Pugh score A or B accompanied with multiple tumors and extrahepatic metastases and relatively good performance status (PS) (1-2). Patients may receive newer agents derived from potential findings of RCTs.
The HCC patients with Child-Pugh C status at any tumor stage and below-par PS (>2) belong to stage D (terminal phase). The patients with an end-stage disease condition receive a recommendation for symptomatic treatment (Cillo et al., 2006; Chen et al., 2009).
Kudo et al. (2003) proposed the Japan Integrated Staging System (JIS). This system's basis was a cohort study employing 722 patients who had undergone treatments at two Japanese institutions. JIS score is a compiled system of Child-Pugh grade and Japanese TNM developed by the Liver Cancer Study Group of Japan (LCSGJ) (Makuuchi et al., 2003). The three parameters, such as vascular invasion, single and multiple nodules, and their diameter, either < or > 20 cm, are backbones of the JIS scoring system. In JIS staging, the patients receive a scoring of 0, 1, and 2 based on Child-Pugh status A, B, C, D, respectively. Subsequently, the scores such as 0, 1, 2, and 3 have become with Japanese TNM staging I, II, III, and IV, respectively. The summation of these scores finally divides patients into six groups (0-5) (Kudo et al., 2004; Toyoda et al., 2005). The cumulative 10-year survival rates of patients with the JIS system and with the Italian program (CLIP) were 65% and 23%, respectively, indicating the significantly superior ability of the JIS system in stratifying of early diagnosed HCC patients (Kudo et al., 2004; Toyoda et al., 2005). In the exiting JIS staging system, replacing the encephalopathy component with indocyanine green clearance (ICG-R15) achieves more effective and timely HCC-screening. Further refinement has made prognosis prediction highly accurate by the JIS system, leading to biomarker combined JIS (bm-JIS). The biomarkers included in bm-JIS are α-fetoprotein (AFP), AFP-Lens culinaris agglutinin-reactive (AFP-L3), and des-gamma-carboxy prothrombin (DCP) (Ikai et al., 2006; Kitai et al., 2008). This staging system's performance remained unassessed in HCC-patients of Western countries, where HCC has been detected at the early stage (Karademir 2018).
The retrospective analysis of 435 patients undergoing treatment at 16 Italian institutions led to CLIP development in 1998 (the cancer of the Liver Italian Program (CLIP) investigators. 1998). The fundamental focus behind the development of CLIP was to overcome the shortcomings associated with the TNM staging. Child-Pugh status of the patients, tumor morphology and extension, portal vein thrombosis, and AFP levels are the fundamental components of CLIP score (Farinati et al., 2000; Llovet and Bruix, 2000; Ueno et al., 2001). Each of the sub-component under these variables receives a Scoring system. For example, Child-Pugh status, A, B, and C are similar to scores 0, 1, 2. Based on the variable tumor morphology and extension, the characteristics, namely, uninodular and extension ≤50 percent, multinodular and extension ≤50 percent, and massive or extension >50 percent, depict scores 0, 1, 2, respectively. The levels of AFP <400 and > 400 have been assigned with scores 0 and 1, respectively. The presence and the absence of portal vein thrombosis have scores of 0 and 1, respectively. The final CLIP score is the summation of all the subscores, and depending on the final score, patients have been stratified into six groups (0-6). The CLIP calculation is very facile and well-coordinated with survival (Liu et al., 2016). The lower number signifies a superior prognosis as compared to a higher number. CLIP score fails to provide conclusive information regarding the impact of underlying liver diseases, performance status, and extrahepatic metastasis on the outcomes. Notably, the CLIP score is incapable of predicting the appropriate therapy for the HCC-patients. The prospective CLIP validation findings in 196 patients revealed that the CLIP score's predictive potency was significantly superior to the Okuda staging system (Liu et al., 2016). Even though several cohort studies (Canadian, Italian and Japanese) had externally validated the CLIP score, the main disadvantage is that it fails to predict early-stage HCC patients who could benefit from radical treatment (Pons et al., 2005).
A study consisting of 850 patients first proposed the Okuda system in 1985 (Okuda et al., 1985). The factors of the Okuda staging include the size of the tumor (≤ or > 50% of the entire liver), the presence of ascites, levels of serum albumin (≤ or > 3.0 g/dL), and bilirubin levels (≤ or > 3.0 mg/dL). The variables assessment has resulted in a classification of HCC-patients into three stages. They are, namely, I (not advanced), II (moderately advanced), and III (very advanced) (Shouval, 2002). The Okuda system is the most widely explored classification system in Western countries (Cillo et al., 2006; Liu et al., 2016). Briefly, the Okuda system is an integrated system capable of addressing the extent of underlying cirrhosis and tumor features from a single platform (Pons et al., 2005). In the past, normally, HCC cases were diagnosed at the advanced stage, making a huge impact on the popularity and acceptability of the Okuda system. The advancement in surveillance and imaging techniques makes a remarkable impact on HCC diagnosis, and nowadays, patients are diagnosed efficiently at an early asymptomatic stage of disease (Karademir 2018). Further, the probability of the tumor occupying half of the liver space nowadays is a remote possibility leading to the loss of glory of the Okuda system. Importantly, Okuda is incapable of differentiating moderately advanced HCC patients; thus, the Okuda system's major focus is identifying patients with the end-stage disease to exclude from therapeutic trials due to their inferior prognosis (Rabe et al., 2003; Giannini et al., 2004). The Okuda system is a crude classification system where tumor size is designated arbitrarily (Shouval 2002). The potential shortcomings associated with Okuda staging include the inability to provide information regarding various crucial aspects of the tumor, which greatly impact the prognosis of early phase HCC patients. These include nature of tumour (unifocal/multifocal/diffuse), existence of vascular invasion and size (< 2cm). Moreover, the Okuda system's predictive potential is significantly lower than the modern staging system available for HCC classification (Subramaniam et al., 2013; Karademir, 2018). Despite several disadvantages, till now Okuda system has a global acceptance and is considered as standard. The new scoring system's performance has been analyzed compared to the Okuda stage (Levy et al., 2002; Liu et al., 2016).
The Hong Kong Liver Cancer (HKLC) classification developed by Yau et al. (2014) was on the cohort study employing 3856 HCC patients who were predominantly infected with HBV virus and had undergone treatment at a single institution. Similar to BCLC, HKLC also bridges stages of HCC with the treatment recommendations. The pillars of HKLC are the five established prognostic factors: Eastern Cooperative Oncology Group (ECOG) PS, Child-Pugh grade, condition of the tumor, and presence of extrahepatic vascular invasion metastasis. Based on these prognostic factors, patients had five principal groups and nine subgroups with distinct survival outcomes (Sohn et al., 2017). Compared to BCLC, HKLC has a significantly superior discriminatory potential between patients with moderate tumor-related symptoms and more severe symptoms (Adhoute et al., 2015).
Further, HKLC can recognize patients at intermediate or advanced HCC, probably requiring highly aggressive treatments. Therefore, the patients' survival outcomes are significantly higher in HKLC staging than BCLC due to the potent stratification of patients into distinct groups and intrusive treatment recommendations (Yau et al., 2014; Adhoute et al., 2015; Sohn et al., 2017). Despite its high potential prognostic ability, several issues associated with HKLC have highlighted some critical drawbacks. Firstly, overlapping as observed between nine subgroups of HKLC diminished its clinical applicability. Although reports revealing the decrement of subgroups from 9 to 5 are available, their external validations are still warranted (Adhoute et al., 2015; Sohn et al., 2017). Secondly, the performance of HKLC in non-HBV-related cases is yet to validate. Thus its ability to link the treatment recommendations is specific and may not be generalizable. The pooled data obtained from a prospective European cohort with 1693 patients have revealed that the predictive power of BCLC classification on overall survival was significantly superior to the HKLC counterpart (Kolly et al., 2016). Finally, evidence-based criteria developed for the prognosis assessment revealed that BCLC is the sole classification system that can meet all cancer staging standards (Forner et al., 2018; Yang et al., 2019).
Risk Factors for HCC
Pre-existing cirrhosis links to nearly 70-90% of HCC-patients (Singh et al., 2018; Yang et al., 2019; Balogh et al., 2016; Marrero et al., 2018). Thus, the etiological agents responsible for chronic liver injury lead to cirrhosis and are risk factors for HCC. The prime causes of cirrhosis and HCC include HBV, HCV, alcohol intake, and NAFLD. Other factors contributing to HCC development include hereditary hemochromatosis, primary biliary cholangitis (PBC), and Wilson's disease (Yang et al., 2019; Balogh et al., 2016; Marrero et al., 2018).
Viral hepatitis due to chronic HBV infection and HCV infection makes remarkably significant contributions to HCC development as it accounts for nearly 80% of HCC cases globally (El-Serag, 2012; Yang JD and Roberts, 2010). Chronic HBV infection plays a pivotal role in developing HCC in East African and most African countries, excluding northern Africa, where HCV exhibits its prevalence (Park et al., 2015; Yang et al., 2015). The statistics have revealed that globally, 257 million individuals will develop chronic HBV infection and HBV–associated acute hepatitis, chronic hepatitis, cirrhosis, and HCC, resulting in 20 million deaths between 2015 and 2030 (Yang et al., 2019). Among them, HCC will solely contribute to 5 million deaths. HBV contains a double-stranded circular DNA molecule having eight different genotypes (A-H) in further geographic distribution. For example, the most prevalent genotypes in Europe and the Middle East are A and D. In contrast, the predominant genotypes are C and B in Asia. The development of HCC is significantly higher with genotype C than A, B, and D (Balogh et al., 2016; Marrero et al., 2018). The HBV genome contains four overlapping transcription units which encode nucleocapsid or core protein comprising of hepatitis B core antigen (HBcAg), envelope protein containing hepatitis B surface antigen (HBsAg), polymerase, and the X protein (HBx), having a pivotal role for the development of HCC (Yoon, 2018). Several reports in the literature have revealed that integrating the viral genome with the host genome leads to an oncogenic transformation in hepatic cells upon chronic HBV infection (Sung et al., 2012). The findings of the next-generation sequencing (NGS) study revealed that the integration of the HBV genome occurred in 80% of HBV-positive HCC cases. Further, a more extensive association was with tumor tissues than non-tumor tissues (Nault et al., 2013). Three cancer-associated genes, namely, telomerase reverse transcriptase (TERT), mixed-lineage leukemia 4 (MLL4), and cyclin E1 (CCNE1), were frequently observed at the integration sites in HBV positive tumors, signifying considerably good association between integration sites and hepatic neoplasia. The published literature highlighted that more than 50% of HCC tissues had exhibited mutation in TERT promoter (Sung et al., 2012; Nault et al., 2013). Plenty of pieces of evidence have suggested that HBx performs crucial roles in the development of HCC via a plethora of mechanisms at the cellular and molecular level (Sung et al., 2012; Nault et al., 2013; Bell et al., 2015; Zhang et al., 2012). They include: (a) transactivation of various oncogenes such as Yes-associated protein (YAP), (b) changes in DNA specificity of cyclic AMP (cAMP) -response element-binding protein (CREB) along with the activation of transcription factor 2 (ATF-2) that lead to binding and stimulation of HBV enhancer, (c) modification of DNA binding specificity of p53 suppressor leading to altered expression of its target genes, and (d) regulation of an array of cellular signaling pathways such as Src-dependent pathway, PI3K-Akt pathway, inflammation-associated NF-κβ/STAT-3 and wnt/β-catenin pathway (Sung et al., 2012; Nault et al., 2013; Bell et al., 2015; Zhang et al., 2012; Chan et al., 2013; Cha et al., 2004; Tian et al., 2013). Moreover, HBx has the potential to influence the epigenetic alteration by hypermethylation or hypomethylation of oncogenes and tumor suppressor genes, thus boosting the histone acetylation and deacetylation of tumor-associated genes with the alteration of several microRNAs (miRNAs) (Zhu et al., 2010; Kong et al., 2011; Chen et al., 2013c). The modes of transmission of HBV include contaminated blood transfusions, intravenous injections, and sexual contact. The transmission of infection from mother to fetus through vertical transmission is the predominant cause of HBV infection worldwide. Interestingly, chronic HBV infection has the unique ability to transform normal hepatocytes into neoplastic hepatocytes (Yang et al., 2019; Balogh et al., 2016; Marrero et al., 2018). The hepatocarcinogenesis induced by HBV can be reduced remarkably upon using antiviral agents capable of treating hepatitis B. For example, a significantly superior reduction in 5-year incidence of HCC (13.7% in control vs. 3.7% upon treatment) was available in the literature upon therapy with antiviral agents, especially in cirrhotic patients (Hosaka et al., 2013).
HCV-induced HCC is prevalent in North America, Europe, Japan, parts of central Asia, including Mongolia, northern Africa, and in the Middle East, especially in Egypt (Yoon, 2018; Singh et al., 2018; Yang et al., 2019; Balogh et al., 2016; Marrero et al., 2018). The small single-stranded RNA virus HCV possesses significantly high genetic variability. Western countries and the Far East observe genotypes I, II, and III, while the Middle East follows type IV genotypes (Choo et al., 1991). The genome of HCV is 9.6-kb long, encoding a large polyprotein (Rusyn and Lemon 2014). The cleavage of this protein at the multiple sites leads to the creation of a minimum of 10 proteins along with the structural proteins [core, envelope (E1 and E2)], and non-structural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). Outcomes of various epidemiologic studies revealed that globally HCV is recognized as one of the prime risk factors, leading to the development of HCC (Lerat et al., 2011; Lindenbach et al., 2005). Plenty of studies has revealed the direct influence of HCV to induce malignant transformation, especially the potential of HCV core protein to activate STAT3 via IL-6 autocrine pathway, leading to enhancement in the activity of telomerase (Tacke et al., 2011; Zhu et al., 2010; He et al., 2007). Further, NS4A elevates cells' proliferation by upregulating phosphorylation of extracellular signal-related kinases (ERKs) and inhibiting p53-mediated apoptosis and p21 promoter activity (Kwun et al., 2001, Yu et al., 2012). Apart from the above mechanisms, plenty of evidence in the literature (Korenaga et al., 2005; Munakata et al., 2005; Choi et al., 2006; Tsai et al., 2012) has suggested several mechanisms through which HCV induces oncogenic transformation. They include as follows: (a) oxidative stress resulting in DNA mutagenesis, (b) intense and stable inflammation promoted by NF-κβ, (c) transformation of tumor suppressor genes, (d) direct modulation of the wnt/β-catenin pathway by NS5A, and (e) interaction between TGF-β receptor and NS5A leading to blockade of TGF-β signaling. The presence of pre-existing cirrhosis is the most familiar feature of HCV-induced HCC.
Non-alcoholic steatohepatitis (NASH), a type of NAFLD accompanied by advanced fibrosis, has been observed in patients more than 50 years and who had diabetes or obesity. Annually, NASH's progress to HCC occurs at a rate of 0.5% (Younossi et al., 2016a). Chronic metabolic disorders such as diabetes and obesity significantly increase the chances of HCC. The liver plays a crucial role in glucose metabolism, highlighting the direct impact of diabetes mellitus on the liver resulting in chronic hepatitis, fatty liver, liver failure, and cirrhosis (White et al., 2012; Yang et al., 2017a; Younossi 2016b). The evidence in the literature has recognized diabetes as an independent risk factor of HCC, and the risk of HCC is increased by 2 to 3 folds (Welzel et al., 2013; El-Serag et al., 2006). Plenty of reports in the literature (Mittal et al., 2016; Huang et al., 2018; West et al., 2017) have suggested that failure in the regulation anti-inflammatory pathway cascade loses control of cellular proliferation by the pleiotropic effect of insulin resulting in induction of carcinogenesis. Further, insulin-like growth factor and insulin receptor substrate I can boost cellular proliferation and downregulation of apoptosis, respectively (Park et al., 2010; Balkau et al., 2001; Yoshimoto et al., 2013). Obesity and various hepatobiliary diseases, namely, NAFLD, steatosis, and cryptogenic cirrhosis, may lead to hepatocytes' malignant transformation and induction of HCC (Callee et al., 2003; Reddy and Rao, 2006). Obesity alone boosts the risk of HCC by 1.5 to 4-folds. In overweight subjects and obese patients, the relative risks of HCC were 117% and 189%, respectively (Larson and Wolk 2007). The occurrence of HCC-NAFLD has been observed predominantly in men. The HCC developed in men exhibits significantly reduced fibrosis and cirrhosis, and half of the HCC-NAFLD patients revealed the absence of cirrhosis (Monsour et al., 2013; Turati et al., 2014). Tumors showed a significantly reduced AFP level and elevated des-γ-carboxy prothrombin level than HCV-related HCC (Wakai et al., 2011; Tokushige et al., 2010).
The attributable population fraction (PAF) determines the quantitative assessment of disease risk factors. Evaluation of a population-based study comprising 6,991 HCC- patients more aged than 68 years resulted in the PAF (Welzel et al., 2013). The study's findings revealed that the elimination of diabetes and obesity resulted in a 40% reduction in HCC events. The percentage of decline was much superior upon the elimination of other factors, including HCV. There is a lack of high-quality population-based studies to analyze the association between NAFLD and HCC. However, the preliminary investigations' outcome has suggested that proper assessment of characteristic metabolic syndromes would be the thrust area for effective management and prevention for HCC (Marrero et al., 2018).
Overconsumption of alcohol is a primary global concern as it leads to fatty liver, alcoholic steatohepatitis (ASH), cirrhosis, and finally, resulting in the development of HCC (Schwartz and Reinus 2012). Chronic alcohol consumption activates cytochrome P450 2E1(CYP2E1), a component of cytochrome P450 mixed-function oxidase system, that functions on diverse biological activities such as enhancement of alcohol metabolism, elevation in oxidative stress, hepatotoxicity, and cooperation between several drugs, xenobiotics, and carcinogens (Neuman et al., 2015). Aldehyde produced by alcohol metabolism is crucial for oxidative stress and subsequent liver damage (Yoon 2018). Alcoholic liver disease (ALD) and alcoholic cirrhosis contribute 20-25% and 1.3 -3% of HCC cases annually. The PAF of ALD as a risk factor of HCC ranges between 13-23%, and race and sex play a significant role in the risk factor (Welzel et al., 2013; Massarweh and El-Serag 2017). The function of alcohol as an independent risk factor for HCC potentiates explicitly by the presence of viral hepatitis (Marrero et al., 2018).
Aflatoxin, potent mycotoxins, has strong hepatocarcinogenic effects and can contaminate wide varieties of staple cereals and oilseeds (Yang et al., 2019; Gouas et al., 2009). An area with widespread contamination with aflatoxins exhibits elevated incidences of HCC (Gouas et al., 2009). For example, a faulty post-harvesting process results in exposure of West African countries' general population to aflatoxins. In contrast, there has been a minimum exposure to people of Western countries. The probability of HCC development upon aflatoxin exposure directly depends on the dose and duration. The active form of aflatoxin responsible for hepatocarcinogenesis is aflatoxin B1(AFB1), produced by Aspergillus sp. The principal mechanism of AFB1 includes mutation at codon 249 of tumor suppressor gene TP53 due to the substitution of arginine by serine (R249S), specifically in HCC. The substitution, which accounts for 50-90% of TP53 mutation, is highly predominant in the HCC-patients having high aflatoxin exposure (Weng et al., 2017). The synergy between HBV infection and aflatoxin exposure lends to a remarkable intensification of risk factors of HCC (Yang et al., 2019). Induction of cytochrome P450s by chronic HBV infection boosts inactive AFB1 into an active mutagenic metabolite, AFB1-8, 9-epoxide. The probability of mutation of TP53 by AFB1 has been increased significantly due to hepatocyte necrosis and regeneration induced by chronic HBV infection. Further, HBV onco-
genic protein inhibits the nucleotide excision repair mechanism to remove AFB1-DNA adducts (Yang et al., 2019).
Aristolochic acid (AA), a highly mutagenic compound, is obtained from plants such as Aristolicia and Asarum, which grow worldwide (Arlt et al., 2002). The outcome of the next-generation sequencing (NGS) study revealed that the fraction of HCC patients of Asian origin, especially from China, Taiwan, Vietnam, and South East Asia, showed high mutation rates with similar patterns mutational characteristics that occurred upon exposure to AA. The findings of a large study encompassing 1400 patients revealed that 78%, 47%, 29%, 13%, 2.7%, 4.8%, and 1.7% of HCC patients from Taiwan, China, Southeast Asia, Korea, Japan, North America, and Europe exhibited the signature mutational characters of AA (Rosenquist and Grollman 2016; Ng et al., 2017; Hsieh et al., 2008; Chen et al., 2018). A randomly sampled cohort study comprising of 200,000 patients registered under National Health Insurance in 1997 and 2003 confirmed exposure of one-third of the Taiwanese population to AA (Hsieh et al., 2008).
An estimate that reveals the risk of hereditary hemochromatosis in HCC ranges between 100- 200-folds. Thalassemia (an iron overload state) has no direct correlation with HCC. However, a high prevalence of HCV has been observed in Thalassemic individuals and eventually may increase the risk of HCC in them. Consumption of beer in non-galvanized steel drums increases the risk of HCC than the storage of it in iron resulting in an elevated risk of HCC at least ten times than that of regular iron drums. A population-based cohort study with patients with hereditary hemochromatosis and 5973 members of their first-degree relatives (Elmberg et al., 2003) revealed that HCC was developed in 62 patients having a standardized incidence ratio of 21 (95% confidence interval (CI), 16-22). The risk of developing HCC was more in men than in women, and the incidence risk of developing nonhepatic malignant transformation is nil. Cirrhosis developed from primary biliary cholangitis (PBC) is also recognized as one of the viable risk factors of HCC. A study conducted for three years, with 273 patients with cirrhosis developed from PBC, showed the incidence of HCC was 5.9%. (Marrero et al., 2018) A systemic review comprising 6528 patients with autoimmune hepatitis (AIH) with a median follow-up of 8 years for HCC incidence showed that the pooled incidence rate was 3.1 per person-years, defining AIH as one of the risk factors of HCC (Tansel et al., 2017).
